Biotech Stock Poised For Big Gain Or Big Fall

One Wall Street analyst says there's no middle ground forward for investment in biotech firms, whose products are becoming the focus of scrutiny after big price hikes. Elsewhere, a new multiple sclerosis drug from Roche shows promise, and there's news on a takeover bid by Blackstone and an impending sale by Clayton, Dubilier & Rice of a drug-compounding firm.